Despite this heterogeneity, TAT was efficient, which implies that any radiolabeled anti-hPDL1 mAb bound to one cell expressing PD-L1 would be able to destroy the few surrounding tumor cells, and that targeting is feasible regardless of the total amount of antigenic sites in the tumor. This evidence concerns the gene CD274 and neoplasm.